country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-109081A

Copy Link Print Information

Cedazuridine hydrochloride

Name: Cedazuridine hydrochloride
Brand: MedChemExpress
SKU: HY-109081A
Availability: PreOrder

(Synonyms: E7727 hydrochloride)

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

Cedazuridine (E7727) (Compound 7a) hydrochloride is an orally active cytidine deaminase (CDA) inhibitor with an IC₅₀ value of 0.4 μM. Cedazuridine hydrochloride can be used for cancer research.

For research use only. We do not sell to patients.

Formula: C₉H₁₅ClF₂N₂O₅
Molecular Weight:304.68

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (272 KB)

Cedazuridine hydrochloride Chemical Structure

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (1)
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

IC₅₀: 0.4 μM (CDA)^[1]

All DNA/RNA Synthesis Isoforms :

In Vitro

Cedazuridine (Compound 7a) exhibits superior acid stability^[1].
Cedazuridine (0-10 μM; 72 h) does not enhance effects of AZA (5-Azacytidine, HY-10586) in growth inhibition of AML cell lines^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Cedazuridine (3 mg/kg; p.o.; daily for 7 days) in combination with 2.5 mg/kg AZA shows tumor regression in mice MOLM-13 CDX and PDX models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female NSGS mice, 6–8 weeks old, human cell line-derived (CDX) and primary patient-derived xenograft (PDX) models^[2]
Dosage:

3 mg/kg
Administration:

Oral administration, in combination with 2.5 mg/kg AZA, daily for 7 days
Result:

Led to reduction of leukemic expansion in combination with AZA in a cell line-derived xenograft transplantation, and exhibited preliminary safety and efcacy in a primary AML PDX model.

Animal Model:

NSGS male mice^[2]
Dosage:

1, 3, 10 and 30 mg/kg
Administration:

Oral, in combination with 2.5 mg/kg AZA (Pharmacokinetic Studies)
Result:

Dose-dependently increased the AUC of oral AZA and in comparison to dosing of standard i.p. AZA.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

Molecular Weight 304.68
Formula C₉H₁₅ClF₂N₂O₅
SMILES

[H]Cl.FC1([C@H](N(CC[C@@H](O)N2)C2=O)O[C@H](CO)[C@H]1O)F
Synonyms

E7727 hydrochloride
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (1)

All

Sort by:

Journal Impact Factor

Cancer Res Commun

Mechanisms Underlying Cedazuridine-Mediated Enhancement of Oral Decitabine Bioavailability. [Abstract]

2026 Mar 2. PMID: 41770597

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (272 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Ferraris D, et al. Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase. J Med Chem. 2014 Mar 27; 57(6):2582-8. [Content Brief]

[2]. Ramsey H E, et al. Oral azacitidine and cedazuridine approximate parenteral azacitidine efficacy in murine model. Targeted Oncology, 2020, 15(2): 231-240.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

Cedazuridine hydrochloride

1 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (1)
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Cedazuridine hydrochloride

Publications Citing Use of MedChemExpress (MCE) Cedazuridine hydrochloride

All DNA/RNA Synthesis Isoforms

Biological Activity

Chemical Information

Publications (1)

Purity & Documentation

References

Calculators

Help & FAQs

Cedazuridine hydrochloride Related Classifications

HY-109081A Related Classifications

Bioz